We are live on ! Find out more
NLVP

New Leaf Venture Partners Portfolio holdings

AUM $43M
1-Year Est. Return 25.55%
This Fund
S&P 500
This Quarter Est. Return
+19.43%
1 Year Est. Return
-25.55%
3 Year Est. Return
+17.13%
5 Year Est. Return
+114.46%
10 Year Est. Return
+1,011.57%
AUM
$151M
AUM Growth
+$3.58M
Cap. Flow
-$9.16M
Cap. Flow %
-6.07%
Top 10 Hldgs %
95.41%
Holding
16
New
3
Increased
6
Reduced
2
Closed
2

Sector Composition

Rank Sector Weight
1 Healthcare 87.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ALDR
1
DELISTED
Alder Biopharmaceuticals
ALDR
$34.8M 23.09%
657,783
+24,490
+4% +$891K
ARAV
2
DELISTED
Aravive, Inc. Common Stock
ARAV
$31M 20.57%
339,871
OXFD
3
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$19.1M 12.64%
1,377,497
CMRX
4
DELISTED
Chimerix, Inc.
CMRX
$14.8M 9.82%
320,608
+69,000
+27% +$2.77M
DVAX
5
DELISTED
Dynavax Technologies
DVAX
$14.3M 9.51%
612,498
+205,505
+50% +$4.48M
MRNS
6
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$7.58M 5.02%
163,374
+32,311
+25% +$1.21M
ACAD icon
7
Acadia Pharmaceuticals
ACAD
$5.03B
$7.42M 4.92%
177,230
+44,169
+33% +$1.71M
RLYP
8
DELISTED
RELYPSA INC COM
RLYP
$7.32M 4.85%
221,204
-598,629
-73% -$20.6M
ESPR
9
DELISTED
Esperion Therapeutics
ESPR
$4.07M 2.7%
+49,816
New +$4.88M
KPTI icon
10
Karyopharm Therapeutics
KPTI
$48M
$3.45M 2.28%
8,446
XLRN
11
DELISTED
Acceleron Pharma
XLRN
$2.84M 1.88%
+89,738
New +$2.9M
DERM
12
DELISTED
Dermira, Inc.
DERM
$2.31M 1.53%
+131,590
New +$2.03M
CALA
13
DELISTED
Calithera Biosciences, Inc
CALA
$970K 0.64%
6,795
-21,007
-76% -$4.87M
AKAO
14
DELISTED
Achaogen Inc
AKAO
$800K 0.53%
132,728
+4,000
+3% +$24.8K
SAGE
15
DELISTED
Sage Therapeutics
SAGE
-43,770
Closed -$2.2M
GEVA
16
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
-24,379
Closed -$2.38M

Similar funds

New Leaf Venture Partners's Q2 2015 Portfolio in Review

As of Q2 2015, New Leaf Venture Partners held 16 positions worth $151M, up 2.4% from $147M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

New Leaf Venture Partners withdrew a net $9.16M in Q2 2015, closing 2 positions and reducing 2 holdings. Its most notable exit was SYNAGEVA BIOPHARMA CORP COM STK (DE), an estimated $2.38M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 71% a quarter earlier.

Against the trend, New Leaf Venture Partners opened a new position in Esperion Therapeutics worth $4.07M.

  • New Leaf Venture Partners's largest Q2 2015 buy was Esperion Therapeutics: 49,816 shares worth $4.07M.
  • New Leaf Venture Partners added most to Dynavax Technologies in Q2 2015, an estimated $4.48M increase.
  • New Leaf Venture Partners's biggest Q2 2015 reduction was RELYPSA INC COM, cutting an estimated $20.6M.
  • New Leaf Venture Partners fully exited SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2015, selling an estimated $2.38M.
  • New Leaf Venture Partners's ten largest holdings make up 95% of its $151M portfolio in Q2 2015.
  • New Leaf Venture Partners opened 3 new positions and closed 2 in Q2 2015.
  • New Leaf Venture Partners's portfolio value rose 2.4% quarter-over-quarter to $151M.

Based on New Leaf Venture Partners's 13F filing for Q2 2015, filed 14 Aug 2015.